TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On August 21, 2018, Tonix Pharmaceuticals Holding Corp. (the “Company”) presented the results of the Phase 3 HONOR P301 Study and Phase 2 AtEase P201 Study in a Poster Presentation (the “Poster Presentation”) at the 2018 Military Health System Research Symposium. Copies of the Poster Presentation and the press release that discusses this matter are filed as Exhibits 99.01 and 99.02, respectively, to, and incorporated by reference in, this report.

The Company updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the investor presentations are filed as Exhibits 99.03 and 99.04, and incorporated by reference in, this report.

Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 s112214_ex99-01.htm EXHIBIT 99.01   Exhibit 99.01       Effect of Time Since Trauma on Response to TNX 102 SL* (Cyclobenzaprine Sublingual Tablets) in Military Related PTSD: Results of Two Double Blind Randomized Placebo Controlled StudiesGregory Sullivan,…
To view the full exhibit click here